Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter (Q1) ended March 31, 2025
Context: GSK reported a strong start to 2025, driven by double-digit growth in Specialty Medicines. The company highlighted progress in its R&D pipeline, including two FDA approvals in Q1 (Penmenvy and Blujepa), and reaffirmed its full-year 2025 guidance.
Key Financial Metrics
| Metric | Q1 2025 (£m) | Growth (AER%) | Growth (CER%) |
|---|---|---|---|
| Turnover | 7,516 | +2% | +4% |
| Total Operating Profit | 2,216 | +49% | +50% |
| Total Operating Margin | 29.5% | +9.2 ppts | +9.0 ppts |
| Core Operating Profit | 2,533 | +4% | +5% |
| Core Operating Margin | 33.7% | +0.5 ppts | +0.3 ppts |
| Total EPS | 39.7p | +55% | +56% |
| Core EPS | 44.9p | +4% | +5% |
| Cash Generated from Operations | 1,301 | +16% | - |
| Free Cash Flow | 697 | >100% | - |
| Total Net Debt | 13,947 | - | - |
Note: AER = Actual Exchange Rates; CER = Constant Exchange Rates. Core results are non-IFRS measures.
Material Changes vs. Prior Period
- Profit Surge: Total operating profit and EPS increased significantly (+50% and +56% at CER) primarily due to a reduction in Contingent Consideration Liability (CCL) charges compared to Q1 2024. Core operating profit grew +5% at CER, reflecting underlying business performance.
- Segment Performance:
- Specialty Medicines: Sales grew +17% (CER) to £2.9 billion. Key drivers included HIV (+7%), Respiratory/Immunology (+28%), and Oncology (+53%).
- Vaccines: Sales declined -6% (CER) to £2.1 billion, driven by lower demand for Shingrix (-7%) and Arexvy (-57%), partially offset by Meningitis vaccine growth (+20%).
- General Medicines: Sales were stable at CER, with Trelegy growth (+15%) offsetting declines in legacy products.
- Acquisitions: Net debt increased by £852 million, largely due to the acquisition of IDRx, Inc. (£800 million net cost) and dividend payments.
Guidance, Outlook, and Risks
2025 Full-Year Guidance (at CER)
- Turnover Growth: 3% to 5%
- Core Operating Profit Growth: 6% to 8%
- Core EPS Growth: 6% to 8%
Management Commentary & Pipeline
- Pipeline: GSK expects 5 major FDA approvals in 2025. Q1 approvals included Penmenvy (meningitis) and Blujepa (antibiotic). Further approvals expected for Nucala, Blenrep, and depemokimab.
- Investment: Continued investment in R&D and new asset launches. Completed acquisition of IDRx and new partnerships in neurodegenerative diseases.
- Shareholder Returns: Declared Q1 dividend of 16p (expected full year 64p). Commenced a £2 billion share buyback programme; £273 million executed in Q1.
Risks and Contingencies
- Tariffs: US Administration initiated a Section 232 investigation on pharmaceutical imports. GSK states it is well-positioned with mitigation options.
- Legal: Ongoing Zantac litigation (trials scheduled for 2026); mRNA patent infringement suits filed against Pfizer/BioNTech and Moderna. A global settlement was reached with Pfizer regarding RSV patents.
- Currency: Strengthening Sterling against the Euro and Yen created an adverse currency impact on reported growth.
Investor Verification Checklist
- CCL Volatility: Verify the sustainability of Total EPS growth, which was heavily influenced by lower CCL charges (£2m in Q1 2025 vs £685m in Q1 2024).
- Vaccine Demand: Monitor the trajectory of Shingrix and Arexvy sales, which declined significantly due to market saturation and ACIP recommendation changes.
- Acquisition Integration: Assess the impact of the IDRx acquisition on R&D spend and future oncology pipeline milestones.
- Regulatory Approvals: Track the status of pending FDA approvals for Blenrep, Nucala (COPD), and depemokimab, which are critical to the 2025 guidance.
- Tariff Exposure: Review potential financial impacts of the US Section 232 investigation on pharmaceutical imports.